Novel 1-(2-aryl-2-adamantyl)piperazine derivatives with antiproliferative activity

European Journal of Medicinal Chemistry

Volumn 93, Issue , 2015, Pages 281-290

  Fytas, Christos ^a   Zoidis, Grigoris ^a   Tsotinis, Andrew ^a   Fytas, George ^a   Khan, Mohsin A ^b   Akhtar, Samar ^b   Rahman, Khondaker M ^b   Thurston, David E ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

1 (2 aryl 2 adamantyl)piperazines; In vitro antiproliferative activity; N Boc deprotection; NMR; 1, 2 Binding affinity

Indexed keywords

1 (2 PHENYLTRICYCLO[3.3.1.1 3,7 ]DEC 2 YL) 4 (1 PIPERIDINEACETYL)PIPERAZINE; 1 (2 PHENYLTRICYCLO[3.3.1.1 3,7 ]DEC 2 YL)PIPERAZINE MALEATE; 1 METHYL 4 (2 PHENYLTRICYCLO[3.3.1.1 3,7 ]DEC 2 YL)PIPERAZINE; 1 [(1H IMIDAZOL 1 YL)CARBONYL] 4 (2 PHENYLTRICYCLO[3.3.1.1 3,7 ]DEC 2 YL)PIPERAZINE; 1 [(5 CHLORO 2 THIENYL)CARBONYL] 4 (2 PHENYLTRICYCLO[3.3.1.1 3,7 ]DEC 2 YL)PIPERAZINE; 1 [2 (4 FLUOROPHENYL)TRICYCLO[3.3.1.1 3,7 ]DEC 2 YL] 4 (1 PIPERIDINEACETYL)PIPERAZINE; 1 [2 (4 FLUOROPHENYL)TRICYCLO[3.3.1.1 3,7 ]DEC 2 YL] 4 METHYLPIPERAZINE; 1 [2 (4 FLUOROPHENYL)TRICYCLO[3.3.1.1 3,7 ]DEC 2 YL]PIPERAZINE MALEATE; ADAMANTANE DERIVATIVE; ANTINEOPLASTIC AGENT; BENZYL 4 [2 (4 FLUOROPHENYL)TRICYCLO[3.3.1.1 3,7 ]DEC 2 YL] 1 PIPERAZINECARBOXYLATE; ETHYL 4 (2 PHENYLTRICYCLO[3.3.1.1 3,7 ]DEC 2 YL) 1 PIPERAZINECARBOXYLATE; ETHYL 4 [2 (4 FLUOROPHENYL)TRICYCLO[3.3.1.1 3,7 ]DEC 2 YL] 1 PIPERAZINECARBOXYLATE; GEMCITABINE; PIPERAZINE DERIVATIVE; TERT BUTYL 4 (2 PHENYLTRICYCLO[3.3.1.1 3,7 ]DEC 2 YL) 1 PIPERAZINECARBOXYLATE; TERT BUTYL 4 [2 (4 FLUOROPHENYL)TRICYCLO[3.3.1.1 3,7 ]DEC 2 YL] 1 PERAZINECARBOXYLATE; UNCLASSIFIED DRUG; ADAMANTANE; PIPERAZINE; SIGMA OPIATE RECEPTOR;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING AFFINITY; BRAIN CORTEX; BREAST CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACETYLATION; DRUG BINDING SITE; DRUG CYTOTOXICITY; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; FIBROBLAST; FLUORINATION; HUMAN; HUMAN CELL; HYDROGEN BOND; IN VITRO STUDY; MTT ASSAY; NON SMALL CELL LUNG CANCER; NONHUMAN; PANCREAS CANCER; RAT; STATIC ELECTRICITY; UMBILICAL VEIN ENDOTHELIAL CELL; UTERINE CERVIX CARCINOMA; CELL PROLIFERATION; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; HELA CELL LINE; METABOLISM; TUMOR CELL LINE;

ADAMANTANE; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DESIGN; HELA CELLS; HUMANS; PIPERAZINES; RECEPTORS, SIGMA;

EID: 84923579561     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2015.02.021     Document Type: Article

References (62)

1. N. Kolocouris A. Kolocouris G. B. Foscolos G. Fytas J. Neyts E. Padalko J. Balzarini R. Snoeck G. Andrei E. De Clercq Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2 J. Med. Chem. 39 (1996) 3307-3318
2. G. Zoidis N. Kolocouris J. M. Kelly S. R. Prathalingam L. Naesens E. De Clercq Design and synthesis of bioactive adamantanaminoalcohols and adamantanamines Eur. J. Med. Chem. 45 11 (2010) 5022-5030
3. E. De Clercq Antiviral agents active against influenza A viruses Nat. Rev. Drug Discov. 5 (2006) 1015-1025
4. G. Fytas G. Stamatiou G. B. Foscolos A. Kolocouris N. Kolocouris M. Witvrouw C. Pannecouque E. De Clercq Synthesis and anti-HIV activity of some new aminoadamantane heterocycles Bioorg. Med. Chem. Lett. 7 14 (1997) 1887-1890
5. A. Papadaki-Valiraki S. Papakonstantinou-Garoufalias P. Marakos A. Chytyroglou-Lada M. Hosoya J. Balzarini E. De Clercq Synthesis, antifungal, antibacterial and antiviral effects of some adamantaneketoxime ethers Farmaco 48 (1993) 1091-1102
6. N. Kolocouris G. Zoidis G. B. Foscolos G. Fytas R. S. Prathalingham J. M. Kelly L. Naesens E. De Clercq Design and synthesis of bioactive adamantane spiro heterocycles Bioorg. Med. Chem. Lett. 17 (2007) 4358-4362
7. C. Fytas G. Zoidis N. Tzoutzas M. C. Taylor G. Fytas J. M. Kelly Novel lipophilic acetohydroxamic acid derivatives based on conformationally constrained spiro carbocyclic 2,6-diketopiperazine scaffolds with potent trypanocidal activity J. Med. Chem. 54 (2011) (5250) 5254
8. J.-J. Wang Y.-C. Chen C.-W. Chi K.-T. Huang Y.-T. Chern In vitro and in vivo growth inhibition and G1 arrest in human cancer cell lines by diaminophenyladamantane derivatives Anticancer Drugs 15 7 (2004) 697-705 and the references cited therein
9. J. K. Chakrabarti T. M. Hotten S. Sutton D. E. Tupper Adamantane and protoadamantanealkanamines as potential anti-Parkinson agents J. Med. Chem. 19 (1976) 967-969
10. D. T. Gish R. C. Kelly G. W. Camiener W. J. Wechter Nucleic acids. 11. Synthesis of 5'-esters of 1-. beta.-D-arabinofuranosylcytosine possessing antileukemic and immunosuppressive activity J. Med. Chem. 14 (1971) 1159-1162
11. J. Xu Y. Cao J. Zhang S. Yu Y. Zou X. Chai Q. Wu D. Zhang Y. Jiang Q. Sun Design, synthesis and antifungal activities of novel 1,2,4-triazole derivatives Eur. J. Med. Chem. 46 7 (2011) 3142-3148
12. S. W. McCombie J. R. Tagat S. F. Vice S. I. Lin R. Steensma A. Palani B. R. Neustadt B. M. Baroudy J. M. Strizki M. Endres K. Cox N. Dan C. C. Chou Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: synthesis, antiviral and pharmacokinetic profiles of symmetrical heteroaryl carboxamides Bioorg. Med. Chem. Lett. 13 3 (2003) 567-571
13. S. Kothanahally S. Kumar A. Hanumappa M. Hegde K. H. Narasimhamurthy S. C. Raghavan K. S. Rangappa Synthesis and antiproliferative effect of novel 4-thiazolidinone-, pyridine-and piperazine-based conjugates on human leukemic cells Eur. J. Med. Chem. 81 (2014) 341-349
14. J. S. Yang D. Song B. Lee W. J. Ko S.-K. Park M. Won K. Lee H. M. Kim G. Han Synthesis and biological evaluation of novel aliphatic amido-quaternary ammonium salts for anticancer chemotherapy: Part I Eur. J. Med. Chem. 46 7 (2011) 2861-2866
15. K.-X. Chen Z.-G. Li H.-Y. Xie J.-R. Gao J.-W. Zou Quantitative structure-activity relationship analysis of aryl alkanol piperazine derivatives with antidepressant activities Eur. J. Med. Chem. 44 11 (2009) 4367-4375
16. G. P. Moloney A. Garavelas G. R. Martin M. Maxwell R. C. Glen Synthesis and serotonergic activity of variously substituted (3-amido)phenylpiperazine derivatives and benzothiophene-4-piperazine derivatives: novel antagonists for the vascular 5-HT 1B receptor Eur. J. Med. Chem. 39 4 (2004) 305-321
17. J. Handzlik A. J. Bojarski G. Satåa M. Kubacka B. Sadek A. Ashoor A. Siwek M. WiAcek K. Kucwaj B. Filipek K. KieA-Kononowicz SAR-studies on the importance of aromatic ring topologies in search for selective 5-HT 7 receptor ligands among phenylpiperazine hydantoin derivatives Eur. J. Med. Chem. 78 (2014) 324-339
18. A. Ferle-VidoviA M. Kaštelan D. PetroviA L. Šuman M. Kaselj D. Škare K. Mlinaric-Majerski Synthesis and biological activity of phencyclidine and its adamantylamine derivatives Eur. J. Med. Chem. 28 (1993) 243-250
19. A. Ferle-VidoviA I. JukiA D. Škare L. Šuman L. VukoviA Radioprotective and antitumor activity evaluation of newly synthesized adamantly tenocyclidines Cancer Biother. Radio. 18 5 (2003) 781-790
20. R. Quirion W. D. Bowen Y. Itzhak J. M. Musacchio R. B. Rothman T. P. Su S. W. Tam D. P. Taylor A proposal for the classification of sigma binding sites Trends Pharmacol. Sci. 13 (1992) 85-86
21. S. B. Hellewell A. Bruce G. Feinstein J. Orringer W. Williams W. D. Bowen Rat liver and kidney contain high densities of sigma-1 and sigma-2 receptors: characterization by ligand binding and photoaffinity labeling Eur. J. Pharmacol. 268 (1994) 9-18
22. W. D. Bowen Sigma receptors: recent advances and new clinical potentials Pharm. Acta Helv. 74 (2000) 211-218
23. T. Maurice T. P. Su The pharmacology of sigma-1 receptors Pharmacol. Ther. 124 (2009) 195-206
24. B. J. Vilner C. S. John W. D. Bowen Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines Cancer Res. 55 (1995) 408-413
25. C. S. John B. J. Vilner A. M. Schwartz W. D. Bowen Characterization of sigma receptor binding sites in human biopsied solid breast tumors J. Nucl. Med. 37 (1996) 267P
26. E. Aydar C. P. Palmer M. B. Djamgoz Sigma receptors and cancer: possible involvement of ion channels Cancer Res. 64 (2004) 5029-5035
27. A. Van Waarde A. A. Rybczynska N. K. Ramakrishnan K. Ishiwata P. H. Elsinga R. A. J. O. Dierckx Potential applications for sigma receptor ligands in cancer diagnosis and therapy Biochim. Biophys. Acta (2014) http://dx. doi. org. /10. 1016/j. bbamem. 2014. 08. 022
28. Y. S. Huang H. L. Lu L. J. Zhang Z. Wu Sigma-2 receptor ligands and their perspectives in cancer diagnosis and therapy Med. Res. Rev. 34 (2014) 532-566
29. V. Megalizzi M. Le Mercier C. Decaestecker Sigma receptors and their ligands in cancer biology: overview and new perspectives for cancer therapy Med. Res. Rev. 32 (2012) 410-427
30. W. T. Bem G. E. Thomas J. Y. Mamone S. M. Homan B. K. Levy F. E. Johnson C. J. Coscia Overexpression of sigma receptors in nonneural tumors Cancer Res. 51 (1991) 6558-6562
31. B. Wang R. Rouzier C. T. Albarracin A. Sahin P. Wagner Y. Yang T. L. Smith F. Meric-Bernstam C. M. Aldaz G. N. Hortobagyi L. Pusztai Expression of sigma-1 receptor in human breast cancer Breast Cancer Res. Treat. 87 3 (2004) 205-214
32. E. Aydar P. Onganer R. Perrett M. B. Djamgoz C. P. Palmer The expression and functional characterization of sigma (sigma) 1 receptors in breast cancer cell lines Cancer Lett. 242 (2006) 245-257
33. N. A. Colabufo F. Berardi M. Contino S. Ferorelli M. Niso R. Perrone A. Pagliarulo P. Saponaro V. Pagliarulo Correlation between 2 receptor protein expression and histopathologic grade in human bladder cancer Cancer Lett. 237 (2006) 83-88
34. B. J. Vilner B. R. De Costa W. D. Bowen Cytotoxic effects of sigma ligands: sigma receptor-mediated alterations in cellular morphology and viability J. Neurosci. 15 (1995) 117-134
35. K. W. Crawford W. D. Bowen Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines Cancer Res. 62 (2002) 313-322
36. N. A. Colabufo F. Berardi M. Contino M. Niso C. Abate R. Perrone V. Tortorella Antiproliferative and cytotoxic effects of some 2 agonists and 1 antagonists in tumour cell lines Naunyn-Schmiedeberg's Arch. Pharmacol. 370 (2004) 106-113
37. B. A. Spruce L. A. Campbell N. McTavish M. A. Cooper M. V. L. Appleyard M. O'Neill J. Howie J. Samson S. Watt K. Murray D. McLean N. R. Leslie S. T. Safrany M. J. Ferguson J. A. Peters A. R. Prescott G. Box A. Hayes B. Nutley F. Raynaud C. P. Downes J. J. Lambert A. M. Thompson S. Eccles Small molecule antagonists of the -1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo Cancer Res. 64 (2004) 4875-4886
38. M. S. Ostenfeld N. Fehrenbacher M. Høyer-Hansen C. Thomsen T. Farkas M. Jäättelä Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress Cancer Res. 65 (2005) 8975-8983
39. A. Azzariti N. A. Colabufo F. Berardi L. Porcelli M. Niso G. M. Simone R. Perrone A. Paradiso Cyclohexylpiperazine derivative PB28, a sigma2 agonist and sigma1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer Mol. Cancer Ther. 5 (2006) 1807-1816
40. V. Megalizzi V. Mathieu T. Mijatovic P. Gailly O. Debeir N. De Neve M. Van Damme G. Bontempi B. Haibe-Kains C. Decaestecker Y. Kondo R. Kiss F. Lefranc 4-IBP, a sigma1 receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells, in vitro and sensitizes them in vitro and in vivo to cytotoxic insults of proapoptotic and proautophagic drugs Neoplasia 9 (2007) 358-369
41. H. Kashiwagi J. E. McDunn P. O. Simon Jr. P. S. Goedegebuure J. Xu L. Jones K. Chang F. Johnston K. Trinkaus R. S. Hotchkiss R. H. Mach W. G. Hawkins Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy Mol. Cancer 6 (2007) 48-60
42. A. Piergentili C. Amantini F. Del Bello M. Giannella L. Mattioli M. Palmery M. Perfumi M. Pigini G. Santoni P. Tucci M. Zotti W. Quaglia Novel highly potent and selective sigma 1 receptor antagonists related to spipethiane J. Med. Chem. 53 3 (2010) 1261-1269
43. J. R. Hornick J. Xu S. Vangveravong Z. Tu J. B. Mitchem D. Spitzer P. Goedegebuure R. H. Mach W. G. Hawkins The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine Mol. Cancer 22 9 2010-298
44. R. R. Matsumoto Sigma receptors: historical perspective and background R. R. Matsumoto W. D. Bowen T. P. Su Sigma Receptors: Chemistry, Cell Biology and Clinical Implications (2007) Springer, New York 25-69
45. A. Renaudo V. Watry A. A. Chassot G. Ponzio J. Ehrenfeld O. Soriani Inhibition of tumor cell proliferation by ligands is associated with K+ channel inhibition and p27kip1 accumulation J. Pharmacol. Exp. Ther. 311 2004-1105 1114
46. A. Renaudo S. Lg Hoste H. Guizouarn F. Borgese O. Soriani Cancer cell cycle modulated by a functional coupling between sigma-1 receptors and Clg' channels J. Biol. Chem. 282 (2007) 2259-2267
47. M. Johannessen S. Ramachandran L. Riemer A. Ramos-Serrano A. E. Ruoho M. B. Jackson Voltage-gated sodium channel modulation by sigma-receptors in cardiac myocytes and heterologous systems Am. J. Physiol. Cell Physiol. 296 (2009) C1049-C1057
48. M. Johannessen D. Fontanilla T. Mavlyutov A. E. Ruoho M. B. Jackson Antagonist action of progesterone at -receptors in the modulation of voltage-gated sodium channels Am. J. Physiol. Cell Physiol. 300 2 (2011) C328-C337
49. Y. Ding W. J. Brackenbury P. U. Onganer X. Montano L. M. Porter L. F. Bates M. B. Djamgoz Epidermal growth factor upregulates motility of Mat-LyLu rat prostate cancer cells partially via voltage-gated Na+ channel activity J. Cell. Physiol. 215 (2008) 77-81
50. R. Onkal M. B. A. Djamgoz Molecular pharmacology of voltage-gated sodium channel expression in metastatic disease: clinical potential of neonatal Nav1. 5 in breast cancer Eur. J. Pharmacol. 625 (2009) 206-219
51. K. H. Jansson J. E. Lynch N. Lepori-Bui K. J. Czymmek R. L. Duncan R. A Sikes Overexpression of the VSSC-associated CAM, beta-2, enhances LNCaP cell metastasis associated behavior Prostate 72 10 (2012) 1080-1092
52. S. Riganas I. Papanastasiou G. B. Foscolos A. Tsotinis J. J. Bourguignon G. Serin J. F. Mirjolet K. Dimas V. N. Kourafalos A. Eleutheriades V. I. Moutsos H. Khan S. Georgakopoulou A. Zaniou M. Prassa M. Theodoropoulou S. Pondiki A. Vamvakides Synthesis, 1, 2-receptors binding affinity and antiproliferative action of new C1-substituted adamantanes Bioorg. Med. Chem. 20 (2012) 3323-3331
53. S. Riganas I. Papanastasiou G. B. Foscolos A. Tsotinis G. Serin J. F. Mirjolet K. Dimas V. N. Kourafalos A. Eleutheriades V. I. Moutsos H. Khan S. Georgakopoulou A. Zaniou M. Prassa M. Theodoropoulou A. Mantelas S. Pondiki A. Vamvakides New adamantane phenylalkylamines with -receptor binding affinity and anticancer activity, associated with putative antagonism of neuropathic pain J. Med. Chem. 55 (2012) 10241-10261
54. G. Fytas N. Kolocouris G. B. Foscolos N. Pouli Aminoéthers de quelques aryladamantanols, Chimika Chronika New. Ser. 18 (1989) 47-57
55. K. T. Liu H. C. Sheu Solvolysis of 2-aryl-2-chloroadamantanes. A new Y scale benzylic chlorides J. Org. Chem. 56 9 (1991) 3021-3025
56. T. A. Eaton K. N. Houk S. F. Watkins F. R. Fronczek Geometries and conformational processes in phencyclidine and a rigid adamantyl analog: Variable-temperature NMR, X-ray crystallographic, and molecular mechanics studies J. Med. Chem. 26 4 (1983) 479-486
57. P. Skehan R. Storeng D. Scudiero A. Monks J. McMahon D. Vistica J. T. Warren H. Bokesch S. Kenney M. R. Boyd New colorimetric cytotoxicity assay for anticancer-drug screening J. Natl. Cancer Inst. 82 (1990) 1107-1112
58. Y. P. Keepers P. E. Pizao G. J. Peters J. Van Ark-Otte B. Winograd H. M. Pinedo Comparison of the sulforhodamine B protein and tetrazolium (MMT) assays for in vitro chemosensitivity testing Eur. J. Cancer 27 7 (1991) 897-900
59. K. Dimas S. Hatziantoniou S. Tseleni H. Khan A. Georgopoulos K. Alevizopoulos J. H. Wyche P. Pantazis C. Demetzos Sclareol induces apoptosis in human HCT116 colon cancer cells in vitro and suppression of HCT116 tumor growth in immunodeficient mice Apoptosis 12 4 (2007) 685-694
60. M. E. Ganapathy P. D. Prasad W. Huang P. Seth F. H. Leibach V. J. Ganapathy Molecular and ligand-binding characterization of the sigma-receptor in the Jurkat human T lymphocyte cell line Pharmacol. Exp. Ther. 289 (1999) 251-260
61. W. D. Bowen B. R. De Costa S. B. Hellewell M. Walker K. C. Rice [3H](+)-Pentazocine: a potent and highly selective benzomorphan-based probe for sigma-1 receptors Mol. Neuropharmacol. 3 (1993) 117-126
62. G. B. Brown 3H-Batrachotoxinin-A benzoate binding to voltage-sensitive sodium channels: Inhibition by the channel blockers tetrodotoxin and saxitoxin J. Neurosci. 6 (1986) 2064-2070